As of April 2024 Gilead Sciences has a market cap of $81.57 Billion. This makes Gilead Sciences the world's 200th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.
Year | Market cap | Change |
---|---|---|
2024 | $81.57 B | -19.18% |
2023 | $100.94 B | -6.25% |
2022 | $107.67 B | 18.26% |
2021 | $91.05 B | 24.68% |
2020 | $73.03 B | -11.22% |
2019 | $82.26 B | 2.59% |
2018 | $80.18 B | -14.31% |
2017 | $93.58 B | -0.81% |
2016 | $94.34 B | -34.43% |
2015 | $143.89 B | 1.84% |
2014 | $141.29 B | 22.62% |
2013 | $115.23 B | 106.55% |
2012 | $55.79 B | 81.47% |
2011 | $30.74 B | 5.78% |
2010 | $29.06 B | -25.35% |
2009 | $38.93 B | -16.39% |
2008 | $46.56 B | 8.95% |
2007 | $42.73 B | 42.74% |
2006 | $29.94 B | 23.89% |
2005 | $24.16 B | 53.89% |
2004 | $15.70 B | 26.36% |
2003 | $12.42 B | 84.99% |
2002 | $6.71 B | 5.91% |
2001 | $6.34 B |
On Apr 28th, 2024 the market cap of Gilead Sciences was reported to be:
Name | Market cap | Market cap differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | $352.16 B | 331.70% | ๐บ๐ธ USA |
Pfizer PFE | $143.82 B | 76.31% | ๐บ๐ธ USA |
AbbVie ABBV | $282.63 B | 246.46% | ๐บ๐ธ USA |
Eli Lilly LLY | $697.39 B | 754.90% | ๐บ๐ธ USA |
Amgen AMGN | $144.81 B | 77.51% | ๐บ๐ธ USA |
Biogen BIIB | $30.41 B | -62.72% | ๐บ๐ธ USA |
Illumina ILMN | $19.47 B | -76.13% | ๐บ๐ธ USA |
Vertex Pharmaceuticals VRTX | $102.73 B | 25.93% | ๐บ๐ธ USA |
Merck MRK | $332.33 B | 307.39% | ๐บ๐ธ USA |